NS
Article DetailSEC EDGAR Filings
SEC EDGAR Filings
8-K - Spyre Therapeutics, Inc. - 1.01 / 9.01
Filed:
2026-04-16
AccNo:
0001628280-26-025508
Size:
558 KB
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits
发布时间04/16 20:15 UTC
首次发现04/16 20:20 UTC
热度106.6
重要度78
情绪+0.02
站内整理正文
优先显示结构化正文；如果正文还未抽出，则回退到摘要。
sec_edgar_index_v1 · 714 字符
Form 8-K - Current report: SEC Accession No. 0001628280-26-025508
Filing Date: 2026-04-16
Accepted: 2026-04-16 16:15:12
Documents: 14
Period of Report: 2026-04-14
Items: Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits
Spyre Therapeutics, Inc. (Filer) CIK : 0001636282 (see all company filings) EIN. : 464312787 | State of Incorp.: DE | Fiscal Year End: 1231 Type: 8-K | Act: 34 | File No.: 001-37722 | Film No.: 26867750 SIC : 2834 Pharmaceutical Preparations (CF Office: 03 Life Sciences)
1 | 8-K | syre-20260414.htm iXBRL | 8-K
2 | EX-1.1 | exhibit11-closing8xk.htm | EX-1.1
3 | EX-5.1 | exhibit51-closing8xk.htm | EX-5.1
7 | logo.jpg | GRAPHIC | 2293